Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013
Copyright © 2013 Société française d’anesthésie et de réanimation (Sfar). Published by Elsevier SAS. All rights reserved..
New direct oral anticoagulants (NOAC), inhibitors of factor IIa or Xa, are expected to be widely used for the treatment of venous thromboembolic disease, or in case of atrial fibrillation. Such anticoagulant treatments are known to be associated with haemorrhagic complications. Moreover, it is likely that such patients on long-term treatment with NOAC will be exposed to emergency surgery or invasive procedures. Due to the present lack of experience in such conditions, we cannot make recommendations, but only propose management for optimal safety as regards the risk of bleeding in such emergency conditions. In this article, only dabigatran and rivaroxaban were discussed. For emergency surgery at risk of bleeding, we propose to dose the plasmatic concentration of drug. Levels inferior or equal to 30ng/mL for both dabigatran and rivaroxaban, should enable the realization of a high bleeding risk surgery. For higher concentration, it was proposed to postpone surgery by monitoring the evolution of the drug concentration. Action is then defined by the kind of NOAC and its concentration. If the dosage of the drug is not immediately available, proposals only based on the usual tests, PT and aPTT, also are presented. However, these tests do not really assess drug concentration or bleeding risk. In case of severe haemorrhage in a critical organ, it is proposed to reduce the effect of anticoagulant therapy using a nonspecific procoagulant drug (activated prothrombin concentrate, FEIBA, 30-50U/kg, or non-activated 4-factors prothrombin concentrates 50U/kg). For any other type of severe haemorrhage, the administration of such a procoagulant drug, potentially thrombogenic in these patients, will be discussed regarding concentration of NACO and possibilities for mechanical haemostasis.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Annales francaises d'anesthesie et de reanimation - 32(2013), 10 vom: 30. Okt., Seite 691-700 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Prise en charge des complications hémorragiques graves et de la chirurgie en urgence chez les patients recevant un anticoagulant oral anti-IIa ou anti-Xa direct. Propositions du Groupe d'intérêt en Hémostase Périopératoire (GIHP) - mars 2013 |
|---|
| Beteiligte Personen: |
Pernod, G [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.06.2014 Date Revised 30.03.2022 published: Print-Electronic ErratumIn: Ann Fr Anesth Reanim. 2014 Mar;33(3):198-9 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.annfar.2013.04.016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM230471161 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM230471161 | ||
| 003 | DE-627 | ||
| 005 | 20231224084512.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.annfar.2013.04.016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0768.xml |
| 035 | |a (DE-627)NLM230471161 | ||
| 035 | |a (NLM)23993157 | ||
| 035 | |a (PII)S0750-7658(13)01023-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Pernod, G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013 |
| 246 | 3 | 3 | |a Prise en charge des complications hémorragiques graves et de la chirurgie en urgence chez les patients recevant un anticoagulant oral anti-IIa ou anti-Xa direct. Propositions du Groupe d'intérêt en Hémostase Périopératoire (GIHP) - mars 2013 |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.06.2014 | ||
| 500 | |a Date Revised 30.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Ann Fr Anesth Reanim. 2014 Mar;33(3):198-9 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2013 Société française d’anesthésie et de réanimation (Sfar). Published by Elsevier SAS. All rights reserved. | ||
| 520 | |a New direct oral anticoagulants (NOAC), inhibitors of factor IIa or Xa, are expected to be widely used for the treatment of venous thromboembolic disease, or in case of atrial fibrillation. Such anticoagulant treatments are known to be associated with haemorrhagic complications. Moreover, it is likely that such patients on long-term treatment with NOAC will be exposed to emergency surgery or invasive procedures. Due to the present lack of experience in such conditions, we cannot make recommendations, but only propose management for optimal safety as regards the risk of bleeding in such emergency conditions. In this article, only dabigatran and rivaroxaban were discussed. For emergency surgery at risk of bleeding, we propose to dose the plasmatic concentration of drug. Levels inferior or equal to 30ng/mL for both dabigatran and rivaroxaban, should enable the realization of a high bleeding risk surgery. For higher concentration, it was proposed to postpone surgery by monitoring the evolution of the drug concentration. Action is then defined by the kind of NOAC and its concentration. If the dosage of the drug is not immediately available, proposals only based on the usual tests, PT and aPTT, also are presented. However, these tests do not really assess drug concentration or bleeding risk. In case of severe haemorrhage in a critical organ, it is proposed to reduce the effect of anticoagulant therapy using a nonspecific procoagulant drug (activated prothrombin concentrate, FEIBA, 30-50U/kg, or non-activated 4-factors prothrombin concentrates 50U/kg). For any other type of severe haemorrhage, the administration of such a procoagulant drug, potentially thrombogenic in these patients, will be discussed regarding concentration of NACO and possibilities for mechanical haemostasis | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Guideline | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Anti-IIa | |
| 650 | 4 | |a Anti-Xa | |
| 650 | 4 | |a Anticoagulants oraux | |
| 650 | 4 | |a Chirurgie | |
| 650 | 4 | |a Emergency | |
| 650 | 4 | |a Haemorrhage | |
| 650 | 4 | |a Hémorragie | |
| 650 | 4 | |a Oral anticoagulant | |
| 650 | 4 | |a Reversal | |
| 650 | 4 | |a Réversion | |
| 650 | 4 | |a Surgery | |
| 650 | 4 | |a Urgence | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Benzimidazoles |2 NLM | |
| 650 | 7 | |a Factor Xa Inhibitors |2 NLM | |
| 650 | 7 | |a Morpholines |2 NLM | |
| 650 | 7 | |a Thiophenes |2 NLM | |
| 650 | 7 | |a beta-Alanine |2 NLM | |
| 650 | 7 | |a 11P2JDE17B |2 NLM | |
| 650 | 7 | |a Rivaroxaban |2 NLM | |
| 650 | 7 | |a 9NDF7JZ4M3 |2 NLM | |
| 650 | 7 | |a Thrombin |2 NLM | |
| 650 | 7 | |a EC 3.4.21.5 |2 NLM | |
| 650 | 7 | |a Dabigatran |2 NLM | |
| 650 | 7 | |a I0VM4M70GC |2 NLM | |
| 700 | 1 | |a Albaladejo, P |e verfasserin |4 aut | |
| 700 | 1 | |a Godier, A |e verfasserin |4 aut | |
| 700 | 1 | |a Samama, C M |e verfasserin |4 aut | |
| 700 | 1 | |a Susen, S |e verfasserin |4 aut | |
| 700 | 1 | |a Gruel, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Blais, N |e verfasserin |4 aut | |
| 700 | 1 | |a Fontana, P |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, A |e verfasserin |4 aut | |
| 700 | 1 | |a Llau, J V |e verfasserin |4 aut | |
| 700 | 1 | |a Rosencher, N |e verfasserin |4 aut | |
| 700 | 1 | |a Schved, J F |e verfasserin |4 aut | |
| 700 | 1 | |a de Maistre, E |e verfasserin |4 aut | |
| 700 | 1 | |a Samama, M M |e verfasserin |4 aut | |
| 700 | 1 | |a Mismetti, P |e verfasserin |4 aut | |
| 700 | 1 | |a Sié, P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annales francaises d'anesthesie et de reanimation |d 1993 |g 32(2013), 10 vom: 30. Okt., Seite 691-700 |w (DE-627)NLM012626724 |x 1769-6623 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2013 |g number:10 |g day:30 |g month:10 |g pages:691-700 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annfar.2013.04.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2013 |e 10 |b 30 |c 10 |h 691-700 | ||